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Abstract
Background: The overall incidence of male breast cancer is around 1% of all breast cancers and
is on the rise. In this review we aim to present various aspects of male breast cancer with particular
emphasis on incidence, risk factors, patho-physiology, treatment, prognostic factors, and outcome.
Methods: Information on all aspects of male breast cancer was gathered from available relevant
literature on male breast cancer from the MEDLINE database over the past 32 years from 1975 to
2007. Various reported studies were scrutinized for emerging evidence. Incidence data were also
obtained from the IARC, Cancer Mondial database.
Conclusion: There is a scenario of rising incidence, particularly in urban US, Canada and UK. Even
though more data on risk factors is emerging about this disease, more multi-institutional efforts to
pool data with large randomized trials to show treatment and survival benefits are needed to
support the existing vast emerging knowledge about the disease.
Background
Male breast cancer (MBC) comprises about 1% of all
breast cancers but is found to be on the rise with the
increasing incidence of female breast cancer [1]. The rarity
of this condition precludes large randomized trials. Most
of the information is therefore based on small single insti-
tution retrospective studies or by extrapolation from
breast cancer trials in females. In this review we have tried
to describe all the available information on male breast
cancer with particular emphasis on incidence, etiology,
patho-physiology, clinical features, treatment, prognosis
and survival to find out if any changing trends are emerg-
ing about the disease.
Methods
An online search was made in Pubmed and MEDLINE
databases to find all published studies of interest on male
breast cancer. Searches were performed using the terms
"breast cancer" and "male". The online cancer incidence
database – Cancer Mondial (International Agency for
Research on Cancer, Lyon, France) was also searched to
provide incidence trends of male breast cancer from
1960–2000. Literature was meticulously reviewed and
collated to obtain evidence about various aspects of the
disease reviewed under the following sections.
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Epidemiology
Though MBC is rare, a geographic variation in its inci-
dence has been reported. It is higher in USA and UK than
in Finland and Japan [2]. National Cancer Institute data
on cancer survival in the US shows increase in the inci-
dence of MBC from 0.86 to 1.08 per 100,000 men [1]. An
alarming increasing incidence has been seen in the US and
Canada whereas it is increasing gradually in other parts of
the world as well [3] (Table 1). In the US the highest areas
were New York State and California where the incidence
has been rising since the 1960s. From data on incidence
trends, it seems to be an urban disease in men with high
prevalence in these areas. Data from Africa is scanty. In
Tanzania, it accounts for 6% while in Zambia it is 15% of
all cases of breast cancer [4,5]. Uganda has seen a rising
trend in incidence. In Europe, Scandinavian countries like
Sweden, Denmark and Finland have been seeing increas-
ing incidences as well. About 240 men are diagnosed in
UK each year compared to 40,400 women. There is a doc-
umented increase in the incidence of female breast cancer
[6,7] over the years as well, the rate of rise faster than male
breast cancer. Some studies have even indicated a stable
incidence of MBC [8-11]. The prevalence of MBC
increases with age. Age frequency distribution for males is
unimodal with peak incidence in the late sixth and early
seventh decade. By comparison, females have bimodal
age frequency distribution with early onset incidence at
50 and late at 70 years. The average age of diagnosis in
males is 60 years, which is ten years older than that
noticed in female patients with the disease [8,12]. A large
database review showed differing trends in age based inci-
dences between male and female breast cancers [13] (Fig-
ure 1).
Etiology and risk factors
The definite etiology of MBC is unknown. Factors such as
alteration in hormonal milieu, family history and genetic
alterations are known to influence its occurrence. Various
studies have shown that conditions that alter the estrogen-
testosterone ratio in males predispose to breast cancer
[14,15]. Among these conditions the strongest association
is with Klinefelter's syndrome. Males with this condition
have a fifty times increased risk and accounts for 3% of all
MBC [16]. Conditions, which are associated with
increased estrogen levels, like cirrhosis [17,18] and exoge-
nous administration of estrogen (either in transsexuals or
as therapy for prostate cancer) have been implicated as
causative factors [19-22]. Also, androgen deficiency due to
testicular disease like mumps, undescended testes, or tes-
ticular injury, has been linked to the occurrence of breast
cancer in men [23,24]. Occupational exposure to heat and
electromagnetic radiation, causing testicular damage and
further leading to the development of MBC is also postu-
lated [25,26]. An inherited predisposition for breast can-
cer is noticed in males-analogous to that in females [27-
31]. A positive family history of a first-degree female rela-
tive having breast cancer is seen in up to 15–20% patients
[32]. This increased risk is conferred by mutations in the
breast cancer susceptibility genes (BRCA1 and BRCA2).
Mutations in both the BRCA1 and BRCA2 genes are linked
to female breast cancer. Genetic studies in males however,
have shown that germline mutations in BRCA2 alone
account for the majority of hereditary breast cancer [33-
36]. No link between BRCA1 and familial breast cancer
has been noticed in one study [37], whereas other studies
have suggested a possible link [38,39]. The Cambridge
study showed that 8% of patients had BRCA2 mutations
and all the carriers had a family history of breast, ovarian,
prostate or pancreatic cancer [40]. The highest prevalence
Age wise adjusted incidence of male and female breast cancer (SEER's 12 Registry database, 1992–2000) Figure 1
Age wise adjusted incidence of male and female breast cancer (SEER's 12 Registry database, 1992–2000).World Journal of Surgical Oncology 2008, 6:58 http://www.wjso.com/content/6/1/58
Page 3 of 11
(page number not for citation purposes)
of BRCA2 mutation in MBC has been noted in Iceland
where 40% have the mutation [41]. Several case reports
have linked MBC with other genetic disorders like Cow-
den syndrome [42] and Hereditary Non-Polyposis
Colonic Cancer (HNPCC) [43]. It has been recently
reported that male breast cancer may also predispose to
increased risk of developing a second cancer of the stom-
ach, skin and breast [44].
A strong racial predilection is noted in MBC, with studies
establishing a high-risk for Jews. Among them, the
Sephardic Jews present at a younger age with advanced
stage disease whereas the Ashkenazi Jews have an
increased lifetime risk of suffering from the disease
[45,46]. Gynecomastia, present in 6–38% of MBC
patients has also been implicated as a risk factor [47,48]
and some studies have shown positive correlation
between the two [49]. An interesting study in the US com-
paring incidence, pathology and outcomes in male and
female breast cancer in a defined population showed
more black males than white males to be affected. Also
black men with breast cancer had more involved axillary
lymph nodes and higher stage than whites at presentation
[50]. This is in stark contrast to the high incidence of male
breast cancer preponderance in whites as shown in
another recently reported study in the US which showed
higher incidence in white males, although black males
were more not likely to see an oncologist for considera-
tion of chemotherapy and had higher mortality associated
with the disease (hazard ratio = 3.29; 95% CI, 1.10 to
9.86) [51]. Reports have shown that an association of
MBC and gynecomastia could also represent a chance
occurrence as 35–40% of healthy men have clinical or his-
tological gynecomastia [52].
Alcohol has been variably linked as a causative factor in
the genesis of MBC. A large Swedish study has not shown
any such correlation [53], although it has been implicated
as a causal agent in other studies [54]. A case control study
conducted in Europe has shown that for alcohol intakes of
less than 60 grams per day, the relative risk of MBC is
comparable to that in females, and it continues to increase
at high consumption levels [55]. Other risk factors men-
tioned in various studies are low socioeconomic status,
obesity, pacemakers, tuberculosis and hyperthyroidism
[56,57]. A meta analysis of 7 case-control studies revealed
that the risk of MBC to be significantly increased in males
with the following characteristics; never married, benign
breast disease, gynecomastia, Jewish or history of breast
cancer in a first-degree relative [58-61].
Pathology
The entire spectrum of histological variants of breast can-
cer has been noted in men. Infiltrating ductal carcinoma
is the most predominant subtype with an incidence rang-
ing from 64–93%. The second commonest variant is pap-
Table 1: Changing incidence of male breast cancer. Figures given are Age Standardised Incidence (ASR) per 100,000 population.
Continent Country Volume 1 1960 Volume 4 1975 Volume 6 1985 Volume 8 1995 Volume 9 2000
North America USA (New York State) 0.5 1.1 0.8 1.0 1.1
USA (California) Na 0.6 0.5 0.6 0.7
Canada (Alberta) 0.4 0.7 0.6 0.6 0.5
Canada (Ontario) Na Na 0.6 0.6 0.7
South/Central America Columbia 0.3 0.5 0.4 0.1 0.3
Cuba Na 0.1 0.2 0.3 Na
Brazil (Goiania) Na Na 0.4 0.7 0.8
Europe UK (South Thames) 0.5 0.4 0.5 0.5 0.6
Denmark 0.4 0.4 0.5 0.5 0.6
Sweden 0.4 0.5 0.4 0.4 0.4
Norway 0.3 0.3 0.5 0.4 0.4
Asia Israel (Jews) 1.4 1.1 0.8 1.4 1.1
Japan (Osaka) Na 0.1 0.2 0.2 0.2
India (Mumbai) Na 0.3 0.4 0.3 0.4
China (Shanghai) Na 0.5 0.3 0.3 0.4
Africa Uganda 0.3 Na Na 0.1 1.4
A l g e r i a N aN a0 . 80 . 70 . 6
Mali Na Na 0.8 0.8 Na
Australia New South Wales Na 0.7 0.7 0.6 0.7
Note: Na-data not available.World Journal of Surgical Oncology 2008, 6:58 http://www.wjso.com/content/6/1/58
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illary type seen in 2.6–5% [59-61]. Since the lobular
system is not well developed in men, lobular carcinoma is
uncommon, although, some cases have been reported in
literature [62]. Medullary, tubular, small cell and muci-
nous carcinoma constitute less than 15% of the cases [63].
Rare tumors like inflammatory carcinomas and sarcomas
have also been described [64,65]. Metastasis to breast
from tumors of prostate and lung is known [66,67]. In
some series most of the tumors were noted to be of high-
grade [68] whereas other series have shown predomi-
nance of grade 1 and grade 2 tumours [69]. In another
study 94% of the tumors were noted to be of grade 1 and
2 [70,71].
Several molecular markers have been identified and stud-
ied in MBC patients and include ER (estrogen receptor),
PR (progesterone receptor), AR (androgen receptor), p53
gene, Her2neu (Human Epidermal Growth factor-2)
expression, gelatinases, p27 gene, MIB-1 (Ki67) index,
and Bcl-2 (B-cell lymphoma-2) gene. A high ER positivity
as compared to female breast cancer has been noticed
consistently in studies on MBC. Approximately 64–85%
of cancers in men are ER positive and more than 70% are
PR positive [72-74]. Such high levels of positivity may be
due to low estrogen levels leaving receptors available for
binding and is probably responsible for good hormonal
control [75]. A recent study has however shown that like
females, the ER positive status does increase with age [76].
Androgen receptor status has been variably reported as
being from negative to 95% positive, and its correlation
with clinico-pathological factors and survival is not well
defined [77]. It has been shown to both stimulate and
inhibit growth of AR positive breast cancer lines in vitro
[78]. One study proposed that decrease of AR action in the
breast might predispose to earlier development of MBC
[79]. p53 has been reported to be positive in 21–95% of
MBC [80-82]. It is a tumor suppressor gene that regulates
cell growth by inducing blockage in the cell cycle. Its over
expression has been correlated with recurrence and poorer
prognosis in some patients [83] whereas no such correla-
tion has been found in others [84,85]. Levels of ER, PR
and AR among MBC patients have been summarized in
various studies [1,77,80-82,86,87] (Table 2).
Her2-neu/c-erbB-2
This is a proto-oncogene, which codes for a tyrosine-
kinase transmembrane receptor. Its expression in women
is seen in 20–30% of breast cancers and indicates a poor
prognosis. In MBC over-expression of Her2-neu correlates
significantly with probability of relapse, increased staging,
and higher grades of the carcinoma [88-90].
Gelatinases
Increased gelatinolytic activity of these enzymes (MMP-2,
MMP-9) in MBC patients has been reported in a study to
be related to increased tendency to metastasis and poor
prognosis [91].
p27 and MIB-1
Tumour expression of proliferation marker (MIB-1) and
cell cycle related protein (p27) have shown to be good
predictors of lymph node metastasis in MBC [92].
Bcl-2
Is a proto-oncogene that inhibits apoptosis and helps pro-
mote cell growth. In women with breast cancer, studies
have shown it to be associated with a favourable progno-
sis [93,94] but its role in MBC is yet to be defined.
A recent study has evaluated the role of new protein mark-
ers p21Waf1 and p27Kip1 as predictors of the most effi-
cient endocrine response [95].
Clinical features
The typical clinical presentation of breast cancer in 75%–
95% of men is a hard eccentric non-tender mass [96]. The
mean diameter is reported as 3–3.5 cm but can range from
0.5–12.5 cm. Skin ulceration may be present in a signifi-
cant number of patients [97]. Collective reviews have
shown predilection for the left side in a ratio of 1.07:1.
Nipple involvement manifesting as retraction, nipple dis-
charge, fixation or eczema is seen in 40–50% patients.
This early presentation of late stage disease is attributed to
the small bulk of breast tissue and the central location of
these tumours. Paget's disease has been reported in up o
5% of cases. Less common presentations are breast tender-
ness, itching or symptoms of distant metastasis [98]. Bilat-
Table 2: ER, PR and AR expressions in various studies
Study Number of patients ER (%) PR (%) AR (%)
Giordano S et al., [1] 1113 55.3 48.2 Na
Pich A et al., [77] 47 Na Na 34
Andre S et al., [80] 90 72 74 0
Mourao NettoM et al., [81] 48 75 69 Na
Shpitz B et al., [82] 26 81 Na Na
Kwiatkowska D et al., [86] 43 61.5 71.8 38.5
Rayson D et al., [87] 77 91 96 95
Note: Na-data not availableWorld Journal of Surgical Oncology 2008, 6:58 http://www.wjso.com/content/6/1/58
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eral MBC has been reported in 1.9% patients [99]. Axillary
lymph node involvement is very common and clinically
suspicious adenopathy has been seen in 40–55% patients.
This is explained on the basis of lack of awareness and
delayed diagnosis as compared to females. Biologically
however, MBC is less aggressive than that in women
[100].
A population-based study has shown lymphadenopathy
in 37.7% male and 29.2% female patients. Men are 1.6
times more likely to have axillary involvement as com-
pared to females. This study also showed that 6.9% males
presented with distant metastasis unlike 5.6% females
[101]. The mean duration of symptoms before diagnosis
has been reported to be 14–21 months in older studies
and 1–8 months in more recent ones [102,103].
Investigations
The paucity of breast tissue in males makes it difficult to
perform and interpret imaging techniques like ultrasound
(US) and mammography as compared to females. US has
not been shown to be useful in diagnosing MBC [104].
Mammography has however shown to be useful in diag-
nosing breast cancer in most studies. It forms less than 1%
of mammographic examinations done in breast imaging
centres [105]. A study of 100 mammograms from Dallas,
Texas concluded that sensitivity of mammography was
92%, specificity 90%, positive predictive value 55% and
negative predictive value 99% and accuracy of 90% [106].
Mammography can also help to distinguish between
benign and malignant lesions of the male breast. The
mammographic characteristics in male breast cancer are
more likely to show a mass lesion, rather than micro cal-
cifications [105]. Fine needle aspiration cytology (FNAC)
is a reliable investigation modality in MBC and helps to
differentiate benign from malignant lesions. In a large
study (614 cases of males with breast lesions) conducted
by John Hopkins Institute USA showed a sensitivity of
95.3%, specificity of 100% and diagnostic accuracy of
98% for FNAC [107]. Other techniques like TC-99m Ses-
tamibi uptake scan have been tried for the diagnosis of
malignant masses in males [108].
Prognosis
A number of variables have been reported to affect prog-
nosis in MBC patients. Among these, tumour stage [1,109-
111] (Figure 2) and axillary nodal status [77,108,112]
have consistently been shown to be the most important
independent predictors of overall survival. Giordano et
al., showed [1] five year overall survival rates to be 78%
for patients with stage I, 67% with stage II, 40% with stage
III, and 19% with stage IV MBC. The five-year survival for
patients with node negative disease has been shown in
another series to be approximately 70% and that for node
positive disease ranging from 37% to 54% [113].
The grade of the tumour has been shown to affect progno-
sis significantly in univariate analysis. However, the sig-
nificance of this association is not noted in multivariate
analysis [114]. In non-disseminated cases, tumour size
and the nodal status were the most important prognostic
indicators. Five-year survivals range from 74% for
tumours less than 2 cm to 37% for those more than 5 cm
in size [115]. One study of 65 MBC cases reported the
clinical stage to be the single most significant factor-affect-
ing prognosis irrespective of tumour size or lymph node
metastasis [83]. Another study however showed that axil-
lary lymph node status on multivariate analysis was the
only prognostic parameter of statistical significance [116].
Though recent studies have provided prognostic informa-
Stage related survival in male breast cancer Figure 2
Stage related survival in male breast cancer.World Journal of Surgical Oncology 2008, 6:58 http://www.wjso.com/content/6/1/58
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tion of molecular markers in MBC, the comparative
results from these studies are conflicting.
ER and PR positivity is believed to be prognostically
favourable in MBC similar to breast cancer in females
[78]. However several studies have found that though ER
positivity predicted better overall survival in univariate
analysis, this difference was no longer significant after
adjustments for tumour size, lymph node status and age
were made [1,32,83,117]. The role of AR as a prognostic
factor is also controversial and most studies have shown a
lack of association between AR and survival [77]. In con-
trast, a recent study has demonstrated that AR expression
significantly predicts shorter disease free and overall sur-
vival rates [117]. Over expression of c-erbB2 has been
associated with shortened survival for patients in some
studies [86] whereas others have failed to demonstrate a
similar correlation [118-120]. Similarly, p53 mutation
has been linked to poor survival and increased local recur-
rence in some series unlike others where no such link
could be shown [83,119]. Similar inconsistent results
have also been demonstrated for a variety of other molec-
ular markers like c-myc, MIB-1 DNA ploidy and Her2 neu.
BRCA2 associated tumours have been significantly associ-
ated with poorer disease free and overall survival rates as
was shown in a study where the disease free survival and
overall survival for BRCA2 positive patients was 28% and
25% respectively whereas that for controls was 86% and
68% [117].
MBC has traditionally been associated with dismal sur-
vival rates as compared to females [27,121]. This is attrib-
uted to the late age of presentation and also to delayed
detection. In studies where male patients were matched
with female patients by stage and age, equivalent overall
survival rates have been shown [1,106,122]. Comparison
of disease specific survival was shown to have statistically
better significant results in males as compared to female
breast cancer patients [123]. The disease free, overall and
relapse free survival rates in MBC patients is seen to be var-
iable in studies [1,32,60,61,63,109,124-128] (Table 3).
Treatment
There are no prospective randomised trials validating the
efficacy of various treatment options in MBC. Manage-
ment of these patients is based largely on evidence
obtained from studies in female breast cancer patients. A
literature review shows that there have been marked
changes in the treatment protocols for MBC, which mir-
rors the changes seen in female breast cancer manage-
ment.
Although radical mastectomy was the treatment of choice
in earlier years, less invasive procedures like modified rad-
ical mastectomy (MRM) or simple mastectomy are now
the standard procedure. A number of series have not
shown improvement in survival or local recurrence for
male patients who underwent more radical procedures
[106,129,130]. Conservative breast surgery in the form of
lumpectomy has been reported for Stage-I and ductal car-
cinoma in-situ (DCIS). As in female breast cancer series,
lumpectomy alone results in unacceptably high rates of
local recurrence, which is reduced upon addition of local
radiotherapy (RT) [60]. There is a lack of uniformity in lit-
erature regarding the indications and role of postoperative
RT in MBC. Interpretation of results from the literature is
difficult because most of the studies do not have matched
controls for tumour size, nodal status or stage. There have
been recommendations for its routine use as it is felt that
lack of sufficient breast tissue prevents wide clearance
margins on surgery [131,132]. Some studies have even
suggested routine inclusion of the internal mammary
chain in the radiation field [133]. This approach has how-
ever been challenged by others who have shown low local
recurrence rates in patients who underwent surgery alone
without RT [134,135]. Historically no survival advantage
has been noted with the use of adjuvant radiotherapy. Its
value is however similar to female situations where a sur-
Table 3: Survival after treatment of male breast cancer.
Study Number of 
patients
Period of diagnosis 
(from-to)
5 year overall 
survival (%)
10 year overall 
survival (%)
5 year recurrent 
free survival (RFS)
Giordano et al., [1] 2537 1973–1998 63 41 Na
Goss et al., [32] 229 1955–1996 53 Na 47
Cutuli et al., [60] 397 1960–1986 65 38 Na
Donegan et al., [61] 217 1953–1995 50.6 23.7 Na
Borgen et al., [63] 104 1975–1990 88 Na 65
De Perrot et al., [109] 37 1968–1998 Na 44 Na
Herman et al., [124] 65 Na 69.8 59 Na
Hill et al., [125] 142 1973–1994 86 64 Na
Vinod SK et al., [126] 23 1983–1996 66 44 35
Leivonen et al., [127] 42 Na 25 9 Na
Carmalt et al., [128] 42 1958–1996 50 Na Na
Note: Na-data not available.World Journal of Surgical Oncology 2008, 6:58 http://www.wjso.com/content/6/1/58
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vival benefit has been demonstrated for high-risk patients
[136,137].
In an Austrian study, 31 males were irradiated postopera-
tively to the chest wall and 16 patients to the axilla. Nine
patients also received hormone and chemotherapy.
32.2% were Stage II and 35.5% Stage III. Five-year disease
free survival was 100% for Stage I, 56.3% for Stage II and
67.3% for Stage III disease. Local relapse occurred in only
one patient [126]. Another large German study showed a
five-year survival of 59% and 10-year survival of 46%
[138]. However no data suggests which patients should
receive irradiation to the axilla and which to the chest
wall. Therefore a general trend is now noticed towards
limiting post mastectomy RT to high-risk patients with
advanced T stage and or limited nodal involvement.
The concepts in the management of axillary disease in
MBC have changed significantly over the past decade. The
standard of care for axillary treatment till now has been
axillary lymph node dissection. This is however associated
with the attendant risk of significant morbidity. The vali-
dation of sentinel lymph node biopsy (SLNB) as an accu-
rate procedure in female patients has prompted similar
procedure in men. All of these studies have findings,
which compare favourably with the findings of SLNB in
females and hence it is being advocated now as the stand-
ard surgical procedure in male patients [139,140].
Adjuvant therapy
Hormonal therapy
Due to the high positivity of ER in MBC (75–80%), most
cases have an excellent response to hormonal manipula-
tion. Although various methods like orchidectomy, hypo-
physectomy and adrenalectomy have been described,
tamoxifen has shown to have equivalent results as in
females. No randomised control trials have been done in
male patients and most results have been interpreted
using data from female breast cancer patients. No data is
available to suggest the duration of treatment in males but
one large study showed a 56% disease free survival versus
28% at 5 years in patients of MBC in Stage I and operable
Stage 3 disease who were given tamoxifen for 2 years
[141]. All these patients were node positive. We feel that
more studies need to be done to show whether tamoxifen
should be given for 5 years like in women.
Systemic chemotherapy
Although no definite data or trials exist about the role and
efficacy of adjuvant chemotherapy in MBC, various stud-
ies and centre reviews have shown a benefit in survival
and prevention of recurrence [142]. A large study involv-
ing 24 node positive patients treated with cyclophospha-
mide, 5-flourouracil and methotrexate showed a five-year
actuarial survival of 80% with a median follow up of 46
months [143] and hence it is obvious that chemotherapy
is efficacious in node positive men. In a retrospective anal-
ysis of therapy in MBC, it was noticed that the median sur-
vival of patients who underwent surgery alone was 33
months. However, for those patients who received addi-
tional adjuvant therapy in the form of radiation, hor-
mones and chemotherapy, either alone or in
combination, the median survival rose to 86 months (p <
0.003). Adjuvant therapy was most effective in large size,
node positive and poorly differentiated tumours [129].
Therapy for metastatic disease
As in females, MBC can spread to the liver, lungs, brain
and bones. Rare sites like the choroids plexus and orbit
have been documented [144]. There have been cases of
metastasis to the breast from a primary in the colon, nasal
cavity and from a bronchogenic carcinoma [145].
Hormonal therapy has been proven to help in metastatic
disease. Past therapies included orchiectomy, hypophy-
sectomy and adrenalectomy. However these radical and
disfiguring procedures have been given up for medica-
tions like tamoxifen. A study has mentioned response
rates of 32% to 50% for orchiectomy, 17% to estrogens,
43% to steroids, 25% to tamoxifen and 60% to androgens
[146,147]. Tamoxifen has shown its beneficial effect in
visceral dominant, bone dominant and soft tissue domi-
nant metastasis and the response depends on the degree
of ER positivity [148].
Diethylstilbestrol has also been prescribed to patients
having soft tissue disease (breast, chest wall and/or lymph
nodes) with an overall response rate of 38% [149]. Sys-
temic chemotherapy can be used as a second line of ther-
apy in failed hormonal therapy or in ER negative patients.
A study reported response rates of 67% for 5-Flourouracil,
doxorubicin and cyclophosphamide, 55% for doxoru-
bicin and vincristine, 53% for cyclophosphamide, 33%
for cyclophosphamide, methotrexate and 5-flourouracil,
and 13% for 5-flourouracil [150]. Not much has been
reported about definitive regimens due to small number
of cases.
Discussion
MBC is a rare disease, which presents mostly in the latter
decades of life. It behaves similar to female breast cancer
in most ways. There are important risk factors shown like
family history and Klinefelter's syndrome. Genetically
BRCA-2 mutations are also linked to MBC. 80% of the car-
cinomas are of the infiltrative ductal variety. Lobular car-
cinoma is extremely rare although other pathological
varieties may be seen. Men have a higher rate of ER posi-
tivity, which accounts for good responses with hormonal
agents like tamoxifen. They also express markers likeWorld Journal of Surgical Oncology 2008, 6:58 http://www.wjso.com/content/6/1/58
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Her2-neu, p53 and Cyclin-D1 in similar percentages as
females.
Most males present with advanced clinical stage of the dis-
ease due to a lack of awareness. Diagnosis is with a mam-
mogram and fine needle aspiration cytology (FNAC) or
core biopsy. All patients should be staged completely to
exclude metastasis. The treatment of localised disease is by
performing a modified radical mastectomy. Adjuvant
therapy is mainly tamoxifen as most are strongly ER posi-
tive. Chemotherapy may be useful in node positive and
locally advanced disease although more evidence is
needed for appropriate regimens. The use of adjuvant RT
has not been conclusively proven to reduce local recur-
rence. The treatment of metastatic disease is mainly hor-
monal which has shown good survival in some studies
versus a poor outlook in others. More research and trials
have to be conducted to find out the effect of hormonal
agents like aromatase inhibitors.
Conclusion
The scenario in male breast cancer has been changing with
respect to its rising incidence-particularly in urban US,
Canada and in Uganda. No particular reason for this has
been found. Better understanding of the patho-physiol-
ogy could be possible from emerging data on etiological
factors and molecular markers. It is an acceptable fact that
the phenotype, pathology, treatment, prognosis and sur-
vival of male breast cancer differ in some aspects with that
of female breast cancer. Certain impediments like inabil-
ity to perform randomised trials in male breast cancer due
to low incidence of the disease should prompt efforts at
setting up large multi-institutional, worldwide studies, so
data could be shared and pooled together to enable emer-
gence of meaningful therapies to treat and improve sur-
vival. One of the ways forwards may be by setting up a
worldwide database of all prevalent cases (a task not diffi-
cult in this day and age).
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